Zoetis price target lowered to $223 from $226 at Goldman Sachs

Goldman Sachs analyst Nathan Rich lowered the firm’s price target on Zoetis to $223 from $226 but keeps a Buy rating on the shares. The company’s Q4 earnings missed estimates as Librela sales missed elevated investor expectations, with specific focus on the lack of sequential growth in existing outside U.S. markets and in-line U.S. sales that included a greater stocking benefit, the analyst tells investors in a research note. The firm adds it is looking for stronger Librela uptake in the U.S. to support continued high-single-digit operational growth and double-digit EPS growth in 2025.